Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

Genedrive chief operating officer Allan Brown to step down

Genedrive's COO is stepping down after three years in the role
Genedrive
Genedrive is making changes to its management structure

Genedrive PLC (LON:GDR) said chief operating officer Allan Brown is to leave the company.

Brown will step down after 31 January 2018 to ensure a smooth handover, the company said.

"Allan joined the company in 2014 and has played a key role in the development of the genedrive instrument and tests," said non-executive chairman, Ian Gilham.

"On behalf of the board I'd like to thank Allan for his contributions and wish him the very best in his future plans."

The announcement comes a month after the company’s full year results, which revealed a 13.7% rise in turnover thanks to a rise in development income and improved services income.

READ: Genedrive highlights improved turnover as it releases first full year results since reboot

View full GDR profile View Profile

Genedrive PLC Timeline

Related Articles

blood cells
October 23 2017
“We are delighted to report positive results from the Phase II study. We believe PeproStat is a first-in-class product which could enter the large and growing haemostat market as early as 2020.”
Zelda's Stewart Washer at Proactive's CEO Sessions
November 17 2017
Stewart Washer at Proactive's CEO Sessions this week.
newspaper with word cancer magnified
July 11 2017
"In our view, the potential for SCIB1 [Scancell's skin cancer treatment], as already demonstrated by the survival data, is remarkable," said one broker recently

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use